[HTML][HTML] History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder

C Heidbreder, PJ Fudala, MK Greenwald - Drug and alcohol dependence …, 2023 - Elsevier
Buprenorphine-based medications were first approved by the United States Food and Drug
Administration in 2002 for the treatment of opioid dependence, or opioid use disorder (OUD) …

[PDF][PDF] Practical technology for expanding and improving substance use disorder treatment: telehealth, remote monitoring, and digital health interventions

MM Sweeney, AF Holtyn, ML Stitzer… - Psychiatric Clinics of …, 2022 - Elsevier
Most people with SUDs do not seek treatment. The pandemic has created other obstacles
due to social distancing and other stressors that amplify the incidence of SUD. Patients with …

Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency

TS Bartholomew, HE Tookes, TA Chueng… - Harm Reduction …, 2023 - Springer
Introduction The expanded capacity of syringe services programs (SSPs) in the USA to
integrate telehealth services was largely related to flexibility of buprenorphine prescription in …

Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine

SL Calcaterra, M Martin, R Bottner… - Journal of hospital …, 2022 - Wiley Online Library
Hospital‐based clinicians frequently care for patients with opioid withdrawal or opioid use
disorder (OUD) and are well‐positioned to identify and initiate treatment for these patients …

Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory

JTW Teck, G Zlatkute, A Perez, H Dritschel… - The Lancet …, 2023 - thelancet.com
Telemedicine could improve access to medications for opioid use disorder (MOUD).
Telemedicine-delivered MOUD (TMOUD) has expanded substantially in response to the …

Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective …

E Suarez, TS Bartholomew, M Plesons… - Annals of …, 2023 - Taylor & Francis
Background: At the start of the pandemic, relaxation of buprenorphine prescribing
regulations created an opportunity to create new models of medications for opioid use …

Pregnancy-and parenting-related barriers to receiving medication for opioid use disorder: A multi-paneled qualitative study of women in treatment, women who …

HB Apsley, K Brant, S Brothers, E Harrison… - Women's …, 2024 - journals.sagepub.com
Background: Women face unique barriers when seeking treatment for substance use
disorders, often related to pregnancy and parenting. Objectives: This study adds to the …

Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United …

N Krawczyk, BD Rivera, C King… - Health Affairs …, 2023 - academic.oup.com
Buprenorphine is a highly effective treatment for opioid use disorder (OUD) and a critical tool
for addressing the worsening US overdose crisis. However, multiple barriers to treatment …

Implementation of telemedicine delivery of medications for opioid use disorder in Pennsylvania treatment programs during COVID-19

MN Poulsen, W Santoro, R Scotti… - Journal of Addiction …, 2023 - journals.lww.com
Methods Five health systems with MOUD programs completed questionnaires regarding
their tele-MOUD models and provided aggregated sociodemographic data for MOUD …

[HTML][HTML] Cost-effectiveness of increasing buprenorphine treatment initiation, duration, and capacity among individuals who use opioids

AL Claypool, C DiGennaro, WA Russell… - JAMA Health …, 2023 - jamanetwork.com
Importance Buprenorphine is an effective and cost-effective medication to treat opioid use
disorder (OUD), but is not readily available to many people with OUD in the US. The current …